- Home
- GRND vs ZLAB Comparison
GRND vs ZLAB Comparison
Compare GRND & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | ZLAB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GRND | ZLAB |
|---|---|---|
| Price | $13.29 | $17.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $22.75 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 1.2M | 828.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $411,545,000.00 | ★ $441,629,000.00 |
| Revenue This Year | $29.03 | $26.16 |
| Revenue Next Year | $21.87 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.97 | 24.14 |
| 52 Week Low | $11.73 | $16.82 |
| 52 Week High | $25.13 | $44.34 |
Technical Indicators
Market Signals| Indicator | GRND | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 32.86 |
| Support Level | $13.23 | $17.18 |
| Resistance Level | $14.24 | $17.97 |
| Average True Range (ATR) | 0.36 | 0.60 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 31.16 | 21.00 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.